Internal medicine journal · 2023
Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.
СтатьяConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Perram Jacinta, Purtill Duncan, Bajel Ashish, Butler Jason, O'Brien Tracey, Teh Benjamin, Gilroy Nicole, Ho Phoebe J, Doocey Richard, Hills Thomas, Perera Travis, Douglas Genevieve, Ramachandran Shanti, Chee Lynette, Trotman Judith, Weinkove Robert, Keogh Steven, Fraser Chris, Cochrane Tara, Watson Anne-Marie, Diamond Peter, Latimer Maya, Irving Ian, Blyth Emily, Cheah Chan, Cole Theresa, Milliken Sam, Yang Hung, Greenwood Matthew, Bardy Peter, Kennedy Glen, Larsen Stephen, Conyers Rachel, Hamad Nada
Аннотация
Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.